Avaliação farmacodinâmica e análise físico-química de duas formulações de propofol usadas em infusão alvo-controlada
Pharmacodynamic evaluation and physical/chemical analysis of two formulations of propofol used in target-controlled infusion
Ricardo Francisco Simoni; Luiz Eduardo de Paula Gomes Miziara; Luis Otávio Esteves; João Gilberto Ribeiro D'Castro; Carlos Alberto Morales Jr; Carlos Eduardo Esqueapatti Sandrin; Thaís Costa Contente; Diogo Oliveira-Silva
Resumo
Palavras-chave
Abstract
Keywords
References
Lilley EM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on propofol emulsion stability. Anaesthesia. 1996;51:815-818.
Fassoulaki A, Paraskeva A, Papilas K, Patris K. Hypnotic and cardiovascular effects of proprietary and generic propofol formulations do not differ. Can J Anaesth. 2001;48:459-461.
Olufolabi AJ, Gan TJ, Lacassie HJ, White WD, Habib AS. A randomized, prospective double-blind comparison of the efficacy of generic propofol with dipriva. Eur J Anaesthesiol. 2006;23:341-345.
Ihmsen H, Jeleazcov C, Schuttler J, Schwilden H, Bremer F. Pharmacodynamics of two different propofol formulations. Anaesthesist. 2006;55:635-642.
Portella AA, Laurancel SM, Rosa DM, Rivera MIM. Estudo comparativo duplamente encoberto entre sevofl urano genérico e Sevorane. Rev Bras Anestesiol. 2010;60:466-474.
Milne SE, Troy A, Irwin MG, Kenny GN. Relationship between bispectral index, auditory evoked potential index and effectsite EC50 for propofol at two clinical end-points. Br J Anaesth. 2003;90:127-131.
Iannuzzi M, Iannuzzi E, Rossi F, Berrino L, Chiefari M. Relationship between bispectral index, electroencephalographic state entropy and effect-site EC50 for propofol at different clinical endpoints. Br J Anaesth. 2005;94:492-495.
Baraka AR, Sutcliffe N, Schwab M. Effect site concentration during propofol TCI sedation: a comparison of sedation score with two pharmacokinetic models. Anaesthesia. 2007;62:661-666.
Struys MMRF, Versichelen L, Rolly G. Influence of preanaesthetic medication on target propofol concentration using "Diprifusor" TCI system during ambulatory surgery. Anaesthesia. 1998;53(^s1):68-71.
Wakeling H, Zimmerman J, Howell S, Glass P. Targeting effect compartment or central compartment concentration of propofol: what predict loss of consciousness. Anesthesiology. 1999;90:92-97.
Ihmsen H, Jeleazcov C, Schuttler J, Schwilden H, Bremer F. Accuracy of target-controlled infusion with two different propofol formulations. Anaesthesist. 2004;53:937-943.
Ackermann BL, Berna MJ, Murphy AT. Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. Curr Top Med Chem. 2002;2:53-66.
Xu RN, Fan L, Riese MJ, El-Shourbagy TA. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Anal. 2007;44:342-355.
RESOLUÇÃO-RDC Nº 31, DE 11 DE AGOSTO DE 2010. .
Thompson KA, Goodale DB. The recent development of propofol (Diprivan). Intensive Care Med. 2000;26(^s4):S400-S404.
Haibo W, Cork R, Rao A. Development of new generation of propofol. Curr Opin Anaesthesiol. 2007;20:311-315.
Baker MT, Naguib M. Propofol: the challenges of formulations. Anesthesiology. 2005;103:860-876.
Prankerd RJ, Stella VJ. The use of oil-in-water emulsions as a vehicle for parenteral drug administration. J Parenter Sci Technol. 1990;44:139-149.
Chansiri G, Lyons RT, Patel MV, Hem SL. Effect of surface charge on the stability of oil/water emulsions during steam sterilization. J Pharm Sci. 1999;88:454-458.
Han J, Davis SS, Washington C. Physical properties and stability of two emulsion formulations of propofol. Int J Pharmaceutics. 2001;215:207-220.
Floyd AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci Technolo Today. 1999;4:134-143.
Nash RA. Pharmaceutical suspensions. 1988:151-198.
Driscoll DF. Examination of selection of light-scattering and light-obscuration acceptance criteria for lipid injectable emulsions. Pharmacopeial Forum. 2004;30:2-11.
Schiche M, Polsinger M, Hermetter A, Prassl R, Zimmer A. In vitro release of propofol and binding capacity with regard to plasma constituents. Eur J Pharm Biopharm. 2008;70:882-888.